3 Stocks Nobody's Talking About That Might Actually Be Worth Talking About

Everyone's busy eulogizing $NFLX after that Q2 guidance whiff. Fine. While the crowd stares at the car crash, let's talk about three names flying well below radar altitude.

$RKLB (Rocket Lab USA) — up 2,200% over two years and still somehow a hidden gem to most retail investors. CNBC's recent coverage of CEO Peter Beck highlighted two massive catalysts: a freshly acquired European laser communications company (Monarch) giving them best-in-class terminal tech, and their positioning as a key contractor for GlobalStar satellites — the same constellation at the center of Amazon's $11.5 billion deal. Vertically integrated, defense-contracted, and riding the SpaceX IPO hype wave without being SpaceX. Criminally underowned.

$IDXG (Interpace Biosciences) — the AI-in-healthcare angle is getting crowded, but molecular diagnostics for thyroid and GI cancers remains brutally niche. With Bloomberg's recent deep-dive on AI-powered early cancer detection showing a 36% stage shift in diagnosis timing, the regulatory and commercial tailwinds for diagnostic genomics companies are real and accelerating. Small float, low coverage, big addressable market.

$LLAP (Terran Orbital) — laser communications and small satellite manufacturing for government and commercial clients, sitting at the exact intersection of the space boom narrative and defense spending. With Rocket Lab's Monarch acquisition validating laser comms as a serious sector, pure-play satellite manufacturers in the sub-$2B market cap range deserve a second look. One meaningful government contract announcement could reprice this overnight.

The next ten-bagger is never the stock everyone's already screaming about on X. It's the boring-sounding one with a weird ticker and a niche you had to Google.